Difference between revisions of "Programmed death-ligand 1"

From Libre Pathology
Jump to navigation Jump to search
Line 4: Line 4:


==General==
==General==
*[[IHC]] testing using a PD-L1 antibody predicts response to anti-PD-L1 drugs.<ref name=pmid26970723/>
*[[IHC]] testing using a PD-L1 antibody (demonstrating positive tumour cells) predicts response to anti-PD-L1 drugs.<ref name=pmid26970723/>


==Prognosis==
==Prognosis==

Revision as of 16:34, 4 May 2016

Programmed death-ligand 1, commonly abbreviated PD-L1, is protein with an important role in immune system regulation, and thus cancer aggressiveness.

It is also known as CD274.[1]

General

  • IHC testing using a PD-L1 antibody (demonstrating positive tumour cells) predicts response to anti-PD-L1 drugs.[2]

Prognosis

Drugs

  • Atezolizumab.[2]

Anti-PD-L1 drugs - use

PD-L1 antibodies are being used to treat:[4]

See also

References

  1. Online 'Mendelian Inheritance in Man' (OMIM) 605402
  2. 2.0 2.1 2.2 Fehrenbacher, L.; Spira, A.; Ballinger, M.; Kowanetz, M.; Vansteenkiste, J.; Mazieres, J.; Park, K.; Smith, D. et al. (Mar 2016). "Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.". Lancet. doi:10.1016/S0140-6736(16)00587-0. PMID 26970723.
  3. Webb, JR.; Milne, K.; Kroeger, DR.; Nelson, BH. (May 2016). "PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.". Gynecol Oncol 141 (2): 293-302. doi:10.1016/j.ygyno.2016.03.008. PMID 26972336.
  4. Gandini, S.; Massi, D.; Mandalà, M. (Apr 2016). "PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis.". Crit Rev Oncol Hematol 100: 88-98. doi:10.1016/j.critrevonc.2016.02.001. PMID 26895815.